CG-P5, a topical peptide eye drop, met safety and efficacy endpoints for wet age-related macular degeneration, according to a presentation at the American Society of Retina Specialists annual meeting.“When we start thinking about the current demand and what we actually need for patients with wet macular degeneration, there’s a clear need for up to 40% of patients who don’t have…
Source: Healio News
